Company Overview and News

 
Singapore sling: Fans take long way round to cheer Demons in the west

2018-09-17 smh.com.au
Desperate Melbourne Demons fans are willing to fly to Perth via overseas cities and pay thousands of dollars in a bid to get to Saturday's Preliminary Final.
FGETF FGHRY

 
Twelve buyers in audacious bid for Adairs

2018-09-07 theage.com.au
Twelve parties, amid a crowd fizzing with money, pumped out more than 90 bids at the auction of 487-495 Bridge Road Richmond on Thursday.
FGETF AYU FGHRY

 
Twelve buyers in audacious bid for Adairs

2018-09-07 smh.com.au
Twelve parties, amid a crowd fizzing with money, pumped out more than 90 bids at the auction of 487-495 Bridge Road Richmond on Thursday.
FGETF AYU FGHRY

 
Macca’s favourite makes a comeback

2018-09-05 ntnews.com.au
McDonalds Australia has announced it will ditch single-use plastic straws in a bid to become more environmentally friendly. The fast-food giant says a trial of paper straws will begin in two stores next month, with a complete phase-out to be achieved by 2020.
FGETF FGHRY

 
Flight Centre's $999 Dublin return on Etihad A380

2018-09-03 nzherald.co.nz
Fares to Dublin on Etihad are on sale for less than $1000 as part of ''earlybird'' European deals.
FGETF FGHRY

3
Why Is Sabre (SABR) Up 7.4% Since Last Earnings Report?

2018-08-30 zacks
A month has gone by since the last earnings report for Sabre (SABR - Free Report) . Shares have added about 7.4% in that time frame, outperforming the S&P 500.
FGETF AMT FGHRY SABR

 
Air New Zealand to London for $1400 in early bird battle

2018-08-27 nzherald.co.nz
The travel industry's "early bird" sales for next year are under way with one agent offering return flights to London on Air New Zealand for just over $1400 and another slashing business class fares by $1000.
FGETF C6L ANZLY AIR FGHRY ANZFF SINGY ANZFY AIZ SINGF

 
Australia's version of Commerce Commission accuses Trivago of deceiving customers with 'best price' claim

2018-08-25 nzherald.co.nz
Trivago has long claimed it offered the "best prices" on hotels. But Australia's consumer watchdog says customers have been deceived.
FGETF FGHRY

 
Flight Centre employees lift the lid on company culture, overcharging customers

2018-08-25 nzherald.co.nz
When it comes to the size and popularity of the world's travel agencies, few hold a candle to Flight Centre.
FGETF FGHRY

 
Political uncertainty pushes ASX lower for the week

2018-08-24 theage.com.au
A volatile week in politics has been matched by swings in the markets, with positive results in the technology sector squeezing holders of short positions against the stocks.
FGETF TPGTF TPPTY FGHRY WTCHF TPM

 
Political uncertainty pushes ASX lower for the week

2018-08-24 smh.com.au
A volatile week in politics has been matched by swings in the markets, with positive results in the technology sector squeezing holders of short positions against the stocks.
FGETF TPGTF TPPTY FGHRY WTCHF TPM

 
FLIGHT CENTRE TRAVEL GROUP LTD ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-23 seekingalpha
The following slide deck was published by FLIGHT CENTRE TRAVEL GROUP LTD ADR in conjunction with their 2018 Q4 earnings call.
FGHRY

 
Political turmoil pushes ASX to 3-week low

2018-08-23 theage.com.au
Political instability in the nation's capital has pushed the Australian sharemarket to its lowest level in three weeks, weighed by the finance and utility sectors.
FGETF FGHRY WTCHF WNARF APA WSA

 
Political turmoil pushes ASX to 3-week low

2018-08-23 smh.com.au
Political instability in the nation's capital has pushed the Australian sharemarket to its lowest level in three weeks, weighed by the finance and utility sectors.
FGETF FGHRY WTCHF WNARF APA WSA

 
Results wrap: ASX continues to fall as political turmoil bubbles over

2018-08-23 abc.net.au
Political turmoil rather than the quality of corporate profits has again dominated trading on the ASX, with the market falling for the fourth successive session.
FGETF DB FGHRY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: AA6352147